Literature DB >> 30565238

WHIM syndrome: Immunopathogenesis, treatment and cure strategies.

David H McDermott1, Philip M Murphy1.   

Abstract

WHIM syndrome is a rare, autosomal dominant immunodeficiency which is named for the four key manifestations: Warts, Hypogammaglobulinemia, Infections, and Myelokathexis. It results from heterozygous gain-of-function mutations in the chemokine receptor CXCR4 which is widely expressed on leukocytes and has profound influences on immune system homeostasis and organogenesis. New treatments for the disease using drugs to reduce CXCR4 function are excellent examples of precision medicine. Since CXCR4 and its ligand CXCL12 play an important role in a variety of infectious, inflammatory, autoimmune, and malignant diseases, the study of WHIM syndrome provides important insights into both the physiologic and disease roles of these molecules. Published 2018. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  bone marrow transplantation; gene therapy; human papillomavirus (HPV); plerixafor; primary immunodeficiency

Mesh:

Substances:

Year:  2019        PMID: 30565238     DOI: 10.1111/imr.12719

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  14 in total

Review 1.  Human genetic dissection of papillomavirus-driven diseases: new insight into their pathogenesis.

Authors:  Vivien Béziat
Journal:  Hum Genet       Date:  2020-05-20       Impact factor: 4.132

Review 2.  WHIM Syndrome: from Pathogenesis Towards Personalized Medicine and Cure.

Authors:  Lauren E Heusinkveld; Shamik Majumdar; Ji-Liang Gao; David H McDermott; Philip M Murphy
Journal:  J Clin Immunol       Date:  2019-07-16       Impact factor: 8.317

Review 3.  Human genetic and immunological dissection of papillomavirus-driven diseases: new insights into their pathogenesis.

Authors:  Vivien Béziat; Jean-Laurent Casanova; Emmanuelle Jouanguy
Journal:  Curr Opin Virol       Date:  2021-09-21       Impact factor: 7.090

4.  Restricted Recruitment of NK Cells with Impaired Function Is Caused by HPV-Driven Immunosuppressive Microenvironment of Papillomas in Aggressive Juvenile-Onset Recurrent Respiratory Papillomatosis Patients.

Authors:  Wei Wang; Yue Xi; Shilan Li; Xiangjun Liu; Guixiang Wang; Hui Wang; Mengmiao Pei; Jie Zhang; Jingang Gui; Xin Ni
Journal:  J Virol       Date:  2022-09-26       Impact factor: 6.549

Review 5.  Human papillomaviruses: diversity, infection and host interactions.

Authors:  Alison A McBride
Journal:  Nat Rev Microbiol       Date:  2021-09-14       Impact factor: 60.633

6.  Alterations in the spatiotemporal expression of the chemokine receptor CXCR4 in endothelial cells cause failure of hierarchical vascular branching.

Authors:  Wenling Li; Chengyu Liu; Nathan Burns; Jeffery Hayashi; Atsufumi Yoshida; Aparna Sajja; Sara González-Hernández; Ji-Liang Gao; Philip M Murphy; Yoshiaki Kubota; Yong-Rui Zou; Takashi Nagasawa; Yoh-Suke Mukouyama
Journal:  Dev Biol       Date:  2021-05-18       Impact factor: 3.148

Review 7.  Inborn Errors of Immunity and Cancer.

Authors:  Alessandra Tiri; Riccardo Masetti; Francesca Conti; Anna Tignanelli; Elena Turrini; Patrizia Bertolini; Susanna Esposito; Andrea Pession
Journal:  Biology (Basel)       Date:  2021-04-09

8.  The negative charge of the 343 site is essential for maintaining physiological functions of CXCR4.

Authors:  Liqing Wang; Qiuhong Xiong; Ping Li; Guangxin Chen; Nayab Tariq; Changxin Wu
Journal:  BMC Mol Cell Biol       Date:  2021-01-23

9.  Trisubstituted 1,3,5-Triazines: The First Ligands of the sY12-Binding Pocket on Chemokine CXCL12.

Authors:  Daniel J Sprague; Anthony E Getschman; Tyler G Fenske; Brian F Volkman; Brian C Smith
Journal:  ACS Med Chem Lett       Date:  2021-10-18       Impact factor: 4.632

Review 10.  Aberrant CXCR4 Signaling at Crossroad of WHIM Syndrome and Waldenstrom's Macroglobulinemia.

Authors:  Samantha Milanesi; Massimo Locati; Elena Monica Borroni
Journal:  Int J Mol Sci       Date:  2020-08-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.